Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Scientific Officer · 10% owner | September 16, 2020 | September 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date September 16, 2020 · Filed September 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 566,249 |
Reported balance
After 2020-09-17 transaction · row 1
1 source rowRow 1 · 2020-09-17 · Grant · Acquired 41,309 · Balance 566,249 F1: Consists of shares of Common Stock issuable under 41,309 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2030-09-15 | Direct | 128,185 |
Reported balance
After 2020-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-16 · Grant · Acquired 128,185 · Balance 128,185 F2: This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of Common Stock issuable under 41,309 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021.
F2: This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2020 Filed Sep 18, 2020 21:12 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 41,309 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025739 · doc4.xml · nonDerivative · entry 1 Subramanian Romesh · CIK 0001824655 · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,249 F1 · shares: Consists of shares of Common Stock issuable under 41,309 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:12 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 128,185 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025739 · doc4.xml · derivative · entry 2 Subramanian Romesh · CIK 0001824655 · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,185 Underlying: Common Stock · 128,185 shares Expires 2030-09-15 F2 · derivative.exercise_date: This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.